The role of the fibrinolytic system in corneal angiogenesis

Angiogenesis

Volumn 6, Issue 4, 2003, Pages 311-316

  Vogten, J Mathijs ^a   Reijerkerk, Arie ^a   Meijers, Joost C M ^a,b   Voest, Emile E ^a   Borel Rinkes, Inne H M ^a   Gebbink, Martijn F B G ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Angiogenesis; Cornea; Fibrinolysis; Plasminogen; Plasminogen activator; Plasminogen activator inhibitor; TAFI

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE RECEPTOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORNEA; CORNEA VASCULARIZATION; ENZYME ACTIVATION; FIBRINOLYSIS; GENE IDENTIFICATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION;

ANIMALS; CARBOXYPEPTIDASE U; CORNEA; FIBRINOLYSIS; FIBROBLAST GROWTH FACTOR 2; MICE; MICE, KNOCKOUT; NEOVASCULARIZATION, PHYSIOLOGIC; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATORS; TISSUE PLASMINOGEN ACTIVATOR; URINARY PLASMINOGEN ACTIVATOR;

ANIMALIA;

EID: 3343006397     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:AGEN.0000029414.24060.fe     Document Type: Article

References (68)

1. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-57.
2. Chang JH, Gabison EE, Kato T, Azar DT. Corneal neovascularisation. Curr Opin Ophthalmol 2001; 12: 242-9.
3. Stetler-Stevenson WG. Matrix metalloproteinases in angiogenesis: A moving target for therapeutic intervention. J Clin Invest 1999; 103: 1237-41.
4. Pepper MS. Extracellular proteolysis and angiogenesis. Thromb Haemost 2001; 86: 346-55.
5. Pepper MS, Ferrara N, Orci L. Montesano R. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun 1991; 181: 902-6.
6. Pepper MS, Wasi S, Ferrara N et al. In vitro angiogenic and proteolytic properties of bovine lymphatic endothelial cells. Exp Cell Res 1994; 210: 298-305.
7. Pepper MS, Rosnoblet C, Di Sanza C, Kruithof EK. Synergistic induction of t-PA by vascular endothelial growth factor and basic fibroblast growth factor and localization of t-PA to Weibel-Palade bodies in bovine microvascular endothelial cells. Thromb Haemost 2001; 86: 702-9.
8. Odekon LE, Blasi F, Rifkin DB. Requirement for receptor-bound urokinase in plasmin-dependent cellular conversion of latent TGF-beta to TGF-beta. J Cell Physiol 1994; 158: 398-407.
9. Mars WM, Zarnegar R, Michalopoulos GK. Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA. Am J Pathol 1993; 143: 949-58.
10. Houck KA, Leung DW, Rowland AM et al. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 1992; 267: 26031-7.
11. George SJ, Johnson JL, Smith MA, Jackson CL. Plasmin-mediated fibroblast growth factor-2 mobilisation supports smooth muscle cell proliferation in human saphenous vein. J Vasc Res 2001; 38: 492-501.
12. Fleury V, Loyau S, Lijnen HR et al. Molecular assembly of plasminogen and tissue-type plasminogen activator on an evolving fibrin surface. Eur J Biochem 1993; 216: 549-56.
13. Pannell R, Black J, Gurewich V. Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained. J Clin Invest 1988; 81: 853-9.
14. Sun Z, Chen YH, Wang P et al. The blockage of the high-affinity lysine binding sites of plasminogen by EACA significantly inhibits prourokinase-induced plasminogen activation. Biochim Biophys Acta 2002; 1596: 182-92.
15. Suenson E, Lutzen O, Thorsen S. Initial plasmin-degradation of fibrin as the basis of a positive feed-back mechanism in fibrinolysis. Eur J Biochem 1984; 140: 513-22.
16. Cesarman GM, Guevara CA, Hajjar KA. An endothelial cell receptor for plasminogen/tissue plasminogen activator (t-PA). II. Annexin II-mediated enhancement of t-PA-dependent plasminogen activation. J Biol Chem 1994; 269: 21198-203.
17. Redlitz A, Fowler BJ, Plow EF, Miles LA. The role of an enolase-related molecule in plasminogen binding to cells. Eur J Biochem 1995; 227: 407-15.
18. Mignatti P, Tsuboi R, Robbins E, Rifkin DB. In vitro angiogenesis on the human amniotic membrane: Requirement for basic fibroblast growth factor-induced proteinases. J Cell Biol 1989; 108: 671-82.
19. Bastaki M, Nelli EE, Dell'Era P et al. Basic fibroblast growth factor-induced angiogenic phenotype in mouse endothelium. A study of aortic and microvascular endothelial cell lines. Arterioscler Thromb Vasc Biol 1997; 17: 454-64.
20. Ambrus JL, Ambrus CM, Toumbis CA et al. Studies on tumor induced angiogenesis. J Med 1991; 22: 355-69.
21. Koolwijk P, van Erck MG, de Vree WJ et al. Cooperative effect of TNFalpha, bFGF, and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix. Role of urokinase activity. J Cell Biol 1996; 132: 1177-88.
22. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995; 270: 14477-84.
23. Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69: 381-7.
24. Wang W, Hendriks DF, Scharpe SS. Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen. J Biol Chem 1994; 269: 15937-44.
25. Tan AK, Eaton DL. Activation and characterization of procarboxypeptidase B from human plasma. Biochemistry 1995; 34: 5811-6.
26. Redlitz A, Tan AK, Eaton DL, Plow EF. Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest 1995; 96: 2534-8.
27. Stewart RJ, Fredenburgh JC, Rischke JA et al. Thrombin-activable fibrinolysis inhibitor attenuates (DD)E-mediated stimulation of plasminogen activation by reducing the affinity of (DD)E for tissue plasminogen activator. A potential mechanism for enhancing the fibrin specificity of tissue plasminogen activator. J Biol Chem 2000; 275: 36612-20.
28. Bajzar L, Nesheim M, Morser J, Tracy PB. Both cellular and soluble forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998; 273: 2792-8.
29. O'Reilly MS, Holmgren L, Shing Y et al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-28.
30. O'Reilly MS, Boehm T, Shing Y et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-85.
31. Reijerkerk A, Mosnier LO, Kranenburg O et al. Amyloid endostatin induces endothelial cell detachment by stimulation of the plasminogen activation system. Mol Cancer Res 2003; 1: 561-8.
32. Reijerkerk A, Voest EE, Gebbink MF. No grip, no growth: The conceptual basis of excessive proteolysis in the treatment of cancer. Eur J Cancer 2000; 36: 1695-705.
33. Dewerchin M, Nuffelen AV, Wallays G et al. Generation and characterization of urokinase receptor-deficient mice. J Clin Invest 1996; 97: 870-8.
34. te Velde EA, Wagenaar, GTM, Reijerkerk A et al. Impaired healing of cutaneous wounds and colonic anastomoses in mice lacking thrombin-activatable fibrinolysis inhibitor. J Thromb Haemost 2003; 2087-96.
35. Carmeliet P, Schoonjans L, Kieckens L et al. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994; 368: 419-24.
36. Ploplis VA, Carmeliet P, Vazirzadeh S et al. Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. Circulation 1995; 92: 2585-93.
37. Drixler TA, Rinkes IH, Ritchie ED et al. Continuous administration of angiostatin inhibits accelerated growth of colorectal liver metastases after partial hepatectomy. Cancer Res 2000; 60: 1761-5.
38. Kenyon BM, Voest EE, Chen CC et al. A model of angiogenesis in the mouse cornea. Invest Ophthalmol Vis Sci 1996; 37: 1625-32.
39. Goldsmith GH Jr. Saito H, Ratnoff OS. The activation of plasminogen by Hageman factor (Factor XII) and Hageman factor fragments. J Clin Invest 1978; 62: 54-60.
40. Colman RW. Activation of plasminogen by human plasma kallikrein. Biochem Biophys Res Commun 1969; 35: 273-9.
41. Twining SS, Wilson PM, Ngamkitidechakul C. Extrahepatic synthesis of plasminogen in the human cornea is up-regulated by interleukins-1alpha and -1beta. Biochem J 1999; 339: 705-12.
42. Drew AF, Kaufman AH, Kombrinck KW et al. Ligneous conjunctivitis in plasminogen-deficient mice. Blood 1998; 91: 1616-24.
43. Kao WW, Kao CW, Kaufman AH et al. Healing of conical epithelial defects in plasminogen- and fibrinogen-deficient mice. Invest Ophthalmol Vis Sci 1998; 39: 502-8.
44. Watanabe M, Yano W, Kondo S et al. Up-regulation of urokinase-type plasminogen activator in corneal epithelial cells induced by wounding. Invest Ophthalmol Vis Sci 2003; 44: 3332-8.
45. McGuire PG, Jones TR, Talarico N et al. The urokinase/urokinase receptor system in retinal neovascularisation: Inhibition by A6 suggests a new therapeutic target. Invest Ophthalmol Vis Sci 2003; 44: 2736-42.
46. Min HY, Doyle LV, Vitt CR et al. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res 1996; 56: 2428-33.
47. Avery RL, Connor TB Jr., Farazdaghi M. Systemic amiloride inhibits experimentally induced neovascularisation. Arch Ophthalmol 1990; 108: 1474-6.
48. Rakic JM, Lambert V, Munaut C et al. Mice without uPA, tPA, or plasminogen genes are resistant to experimental choroidal neovascularisation. Invest Ophthalmol Vis Sci 2003; 44: 1732-9.
49. Oh CW, Hoover-Plow J, Plow E. The role of plasminogen in angiogenesis in vivo. J Thromb Haemost 2003; 1: 1683-7.
50. Ren CJ, Ueda F, Roses DF et al. Irsogladine maleate inhibits angiogenesis in wild-type and plasminogen activator-deficient mice. J Surg Res 1998; 77: 126-31.
51. Levin EG, del Zoppo GJ. Localization of tissue plasminogen activator in the endothelium of a limited number of vessels. Am J Pathol 1994; 144: 855-61.
52. Sato Y, Okamura K, Morimoto A et al. Indispensable role of tissue-type plasminogen activator in growth factor-dependent tube formation of human microvascular endothelial cells in vitro. Exp Cell Res 1993; 204: 223-9.
53. Collen A, Koolwijk P, Kroon ME, Hinsbergh VWM. Influence of fibrin structure on the formation and maintenance of capillary-like tubules by human microvascular endothelial cells. Angiogenesis 1998; 2: 153-65.
54. Brodsky S, Chen J, Lee A et al. Plasmin-dependent and -independent effects of plasminogen activators and inhibitor-1 on ex vivo angiogenesis. Am J Physiol Heart Circ Physiol 2001; 281: H1784-H92.
55. Diaz VM, Planaguma J, Thomson TM et al. Tissue plasminogen activator is required for the growth, invasion, and angiogenesis of pancreatic tumor cells. Gastroenterology 2002; 122: 806-19.
56. Bajou K, Masson V, Gerard RD et al. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J Cell Biol 2001; 152: 777-84.
57. Stack MS, Gately S, Bafetti LM et al. Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation. Biochem J 1999; 340: 77-84.
58. McMahon GA, Petitclerc E, Stefansson S et al. Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J Biol Chem 2001; 276: 33964-8.
59. Gutierrez LS, Schulman A, Brito-Robinson T et al. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. Cancer Res 2000; 60: 5839-47.
60. Ploplis VA, Cornelissen I, Sandoval-Cooper MJ et al. Remodeling of the vessel wall after copper-induced injury is highly attenuated in mice with a total deficiency of plasminogen activator inhibitor-1. Am J Pathol 2001; 158: 107-17.
61. Lambert V, Munaut C, Noel A et al. Influence of plasminogen activator inhibitor type 1 on choroidal neovascularisation. FASEB J 2001; 15: 1021-7.
62. Ge M, Tang G, Ryan TJ, Malik AB. Fibrinogen degradation product fragment D induces endothelial cell detachment by activation of cell-mediated fibrinolysis. J Clin Invest 1992; 90: 2508-16.
63. Meilhac O, Ho-Tin-Noe B. Houard X et al. Pericellular plasmin induces smooth muscle cell anoikis. FASEB J 2003; 17: 1301-3.
64. Reinartz J, Schafer B, Batrla R et al. Plasmin abrogates alpha v beta 5-mediated adhesion of a human keratinocyte cell line (HaCaT) to vitronectin. Exp Cell Res 1995; 220: 274-82.
65. Sugimura M, Kobayashi H, Terao T. Plasmin modulators, aprotinin and anti-catalytic plasmin antibody, efficiently inhibit destruction of bovine vascular endothelial cells by choriocarcinoma cells. Gynecol Oncol 1994; 52: 337-46.
66. Davis GE, Pintar Allen KA, Salazar R, Maxwell SA. Matrix metalloproteinase-1 and -9 activation by plasmin regulates a novel endothelial cell-mediated mechanism of collagen gel contraction and capillary tube regression in three-dimensional collagen matrices. J Cell Sci 2001; 114: 917-30.
67. Stefansson S, Lawrence DA. The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature 1996; 383: 441-3.
68. Czekay RP, Aertgeerts K, Curriden SA, Loskutoff DJ. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J Cell Biol 2003; 160: 781-91.